David Peritt

David Peritt is the Founder and Chief Scientific Officer at Lupagen, where efforts focus on advancing bedside cell therapy through innovative autologous cell modification systems. With an extensive background in academia and industry, David serves as an Adjunct Professor at Northwestern University and holds leadership roles in various organizations, including the Alliance for Regenerative Medicine and the Scientific Advisory Board of Korro Bio, Inc. Previous positions include Chief Scientific Officer at Sigilon Therapeutics, where David led a team that achieved significant milestones, and Program Lead for Tolerance and Cell Therapy at Pfizer. David's experience extends to pivotal roles at Hospira and Johnson & Johnson, emphasizing strategic investments and the development of immunotherapy. David earned a Ph.D. in Immunology from the University of Pennsylvania, an MSc from The Hebrew University of Jerusalem, and a B.Sc. from the University of Maryland.